Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by gleevec (imatinib mesylate)

Cancer Research

Volumn 69, Issue 12, 2009, Pages 5099-5107

  Mukherjee, Joydeep ^a   Kamnasaran, Deepak ^a   Balasubramaniam, Anand ^a   Radovanovic, Ivan ^b   Zadeh, Gelareh ^a,b   Kiehl, Tim Rasmus ^b   Guha, Abhijit ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ANCHORAGE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; HUMANS; MAGNETIC RESONANCE IMAGING; NEURILEMMOMA; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 67449136112     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4475     Document Type: Article

References (42)

1. Rosai J. Ackerman's surgical pathology. 8th St. Louis: Mosby; 1996.
2. Baser ME, Gutmann RE. Neurofibromatosis 2. Curr Opin Neurol 2003;16:27-33.
3. Hajioff D, Raut VV, Walsh RM, et al. Conservative management of vestibular schwannomas: third review of a 10-year prospective study. Clin Otolaryngol 2008;33:255-259 (Pubitemid 351799012)
4. Backous DD, Pham HT. Guiding patients through the choices for treating vestibular schwannomas: balancing options and ensuring informed consent. Otolaryngol Clin North Am 2007;40:521-540, viii-ix. (Pubitemid 46829266)
5. Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro-oncol 2007;9:447-453
6. Johnson WD, Loredo LN, Slater JD. Surgery and radiotherapy: complementary tools in the management of benign intracranial tumors. Neurosurg Focus 2008;24:E2.
7. Koh ES, Millar BA, Menard C, et al. Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital. Cancer 2007;109:1203-1210 (Pubitemid 46435401)
8. Kondziolka D, Lunsford LD, Flickinger JC. Comparison of management options for patients with acoustic neuromas. Neurosurg Focus 2003;14:e1.
9. Rutherford SA, King AT. Vestibular schwannoma management: what is the "best" option? Br J Neurosurg 2005;19:309-316
10. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-521 (Pubitemid 23186636)
11. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;75:826.
12. Giovannini M, Robanus-Maandag E, van der Valk M, et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000;14:1617-1630 (Pubitemid 30460911)
13. Ammoun S, Flaiz C, Ristic N, Schuldt J, Hanemann CO. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 2008;68:5236-5245
14. Diensthuber M, Ilner T, Rodt T, et al. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression. Otol Neurotol 2007;28:559-565 (Pubitemid 47264566)
15. Doherty JK, Ongkeko W, Crawley B, Andalibi A, Ryan AF. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol 2008;29:50-57
16. Koutsimpelas D, Stripf T, Heinrich UR, Mann WJ, Brieger J. Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol 2007;28:1094-1099 (Pubitemid 350191085)
17. Uesaka T, Shono T, Suzuki SO, et al. Expression of VEGF and its receptor genes in intracranial schwannomas. J Neuro-oncol 2007;83:259-266 (Pubitemid 46952236)
18. Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. Curr Opin Otolaryngol Head Neck Surg 2007;15:341-346 (Pubitemid 47373981)
19. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042 (Pubitemid 32267973)
20. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037 (Pubitemid 32267972)
21. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer 2002;38 Suppl 5:S28-36.
22. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N Engl J Med 2002;347:481-487 (Pubitemid 34879335)
23. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480 (Pubitemid 34879334)
24. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-5150 (Pubitemid 30739772)
25. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-3528 (Pubitemid 30487449)
26. Hung G, Faudoa R, Li X, et al. Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int J Oncol 1999;14:409-415
27. Guha A, Lau N, Huvar I, et al. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996;12:507-513 (Pubitemid 26059644)
28. Kamnasaran D, Qian B, Hawkins C, Stanford WL, Guha A. GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci U S A 2007;104:8053-8058 (Pubitemid 47185874)
29. McClatchey AI. Neurofibromatosis. Annu Rev Pathol 2007;2:191-216.
30. Fraenzer JT, Pan H, Minimo L, Jr., Smith GM, Knauer D, Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 2003;23:1493-1500
31. Lepont P, Stickney JT, Foster LA, Meng JJ, Hennigan RF, Ip W. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mut Res 2008;637:142-151 (Pubitemid 350256772)
32. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Sem Oncol 2001;28:27-33. (Pubitemid 33140515)
33. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-3800 (Pubitemid 34534553)
34. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-5783 (Pubitemid 32769094)
35. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004;96:46-55. (Pubitemid 38180959)
36. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-1679 (Pubitemid 35446835)
37. Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 2008;44:501-509
38. Soverini S, Martinelli G, Iacobucci I, Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Exp Rev Anticancer Ther 2008;8:853-864
39. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145 (Pubitemid 30746073)
40. Dentelli P, Rosso A, Balsamo A, et al. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. Blood 2007;109:4264-4271 (Pubitemid 46743392)
41. Fidler I. Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells [Author reply]. Angiogenesis 2008;11:107-108
42. Yan W, Bentley B, Shao R. Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell 2008;19:2278-2288